INZY / Inozyme Pharma, Inc. - SEC Filings, Annual Report, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39397 Inozyme Pharma, Inc. (Exact name of registrant as specifie

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION INOZYME PHARMA, INC.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INOZYME PHARMA, INC. I. The name of the corporation is Inozyme Pharma, Inc. (hereinafter called the “Corporation”). II. The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the board of directors of the Corpo

As filed with the Securities and Exchange Commission on July 1, 2025

POS AM As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

As filed with the Securities and Exchange Commission on July 1, 2025

As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

As filed with the Securities and Exchange Commission on July 1, 2025

As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

As filed with the Securities and Exchange Commission on July 1, 2025

POS AM As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

As filed with the Securities and Exchange Commission on July 1, 2025

As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

As filed with the Securities and Exchange Commission on July 1, 2025

S-8 POS As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

BioMarin Announces Completion of Acquisition of Inozyme

Exhibit (a)(5)(ix) Contacts: Investors Media Traci McCarty Erin Rau BioMarin Pharmaceutical Inc.

BYLAWS INOZYME PHARMA, INC. (A DELAWARE CORPORATION)

Exhibit 3.2 BYLAWS OF INOZYME PHARMA, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation shall be in the City of Wilmington, County of New Castle, State of Delaware or in such other location as the corporation’s board of directors (the “Board of Directors”) may from time to time determine or the business of the corporation may req

As filed with the Securities and Exchange Commission on July 1, 2025

As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) INOZYME PHARMA, INC. (Name of Subject Company (Issu

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Perso

As filed with the Securities and Exchange Commission on July 1, 2025

As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) INOZYME PHARMA, INC. (Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) INOZYME PHARMA, INC. (Name of Subject Company) INOZYME PHARMA, INC. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 4579

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Exhibit 99.1 Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders BOSTON, Mass, June 20, 2025 – Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) INOZYME PHARMA, INC. (Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) INOZYME PHARMA, INC. (Name of Subject Company) INOZYME PHARMA, INC. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 4579

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) INOZYME PHARMA, INC. (Name of Subject Company (Issu

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Perso

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) INOZYME PHARMA, INC. (Name of Subject Company (Issu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Persons (identi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) INOZYME PHARMA, INC. (Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) INOZYME PHARMA, INC. (Name of Subject Company) INOZYME PHARMA, INC. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 4579

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) INOZYME PHARMA, INC. (Name of Subject Company (Issu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Persons (identi

Offer to Purchase for Cash All Outstanding Shares of Common Stock INOZYME PHARMA, INC. $4.00 Net Per Share Pursuant to the Offer to Purchase Dated June 2, 2025 INCLINE MERGER SUB, INC. a wholly-owned subsidiary of BioMarin Pharmaceutical Inc. THE OFF

Exhibit (a)(1)(iii) Offer to Purchase for Cash All Outstanding Shares of Common Stock of INOZYME PHARMA, INC.

Offer to Purchase for Cash All Outstanding Shares of Common Stock INOZYME PHARMA, INC. $4.00 Net Per Share Pursuant to the Offer to Purchase Dated June 2, 2025 INCLINE MERGER SUB, INC. a wholly-owned subsidiary of BioMarin Pharmaceutical Inc. THE OFF

Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of INOZYME PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 INOZYME PHARMA, INC. (Name of Subject Company) I

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 INOZYME PHARMA, INC. (Name of Subject Company) INOZYME PHARMA, INC. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4579

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Persons (identifying status as of

BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, California 94949

Exhibit (d)(4) BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, California 94949 May 10, 2025 Inozyme Pharma, Inc. 321 Summer Street, Suite 400 Boston, MA 02210 Attention: Board of Directors Re: Project Ingrid - Exclusivity Ladies and Gentlemen: BioMarin Pharmaceutical Inc. (“Purchaser”) and Inozyme Pharma, Inc. (the “Company”) wish to continue to engage in negotiations regarding a possible

Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock INOZYME PHARMA, INC. $4.00 Net Per Share INCLINE MERGER SUB, INC. a wholly-owned subsidiary of BIOMARIN PHARMACEUTICAL INC.

Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock INOZYME PHARMA, INC. $4.00 Net Per Share Pursuant to the Offer to Purchase Dated June 2, 2025 INCLINE MERGER SUB, INC. a wholly-owned subsidiary of BioMarin Pharmaceutical Inc. THE OFFER

Exhibit (a)(1)(v) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of INOZYME PHARMA, INC.

MUTUAL NON-DISCLOSURE AGREEMENT

Exhibit (d)(3) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (the “Agreement”), is effective as of May 8, 2024 (the “Effective Date”), and is made by and between BioMarin Pharmaceutical Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. a wholly owned subsidiary of BIOMARIN PHARMACEUTICAL INC. (Names of Filing Persons (Offerors)) Table 1-Tran

Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) INOZYME PHARMA, INC.

Offer to Purchase for Cash All Outstanding Shares of Common Stock INOZYME PHARMA, INC. $4.00 Net Per Share INCLINE MERGER SUB, INC. a wholly-owned subsidiary of BIOMARIN PHARMACEUTICAL INC. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE ONE MINUTE FOLLOWING

Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of INOZYME PHARMA, INC.

LETTER OF TRANSMITTAL to Tender Shares of Common Stock INOZYME PHARMA, INC. $4.00 Net per Share Pursuant to the Offer to Purchase Dated June 2, 2025 INCLINE MERGER SUB, INC. a wholly owned subsidiary of BIOMARIN PHARMACEUTICAL INC. THE OFFER AND WITH

Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of INOZYME PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company) I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company) INOZYME PHARMA, INC. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 45790W108 (CUSIP Num

A SHARED PURPOSE 3

Exhibit 99.2 Introductory Meeting Alexander Hardy President & CEO May 19, 2025 1 Forward-Looking Statements Forward-Looking Statements This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMa

Inozyme Acquisition: An Important Milestone • Deal builds on our 25-year legacy of developing innovative therapies for genetically defined conditions • Acquisition brings to BioMarin INZ-701, a Phase 3 enzyme replacement therapy for treatment of ENPP

Exhibit 99.1 Inozyme Acquisition May 19, 2025 1 Forward-Looking Statements Forward-Looking Statements This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMarin, including, without limitatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Offeror) (Name of Filing Persons (identifying status as offeror, issu

A SHARED PURPOSE 3

Exhibit 99.2 Introductory Meeting Alexander Hardy President & CEO May 19, 2025 1 Forward-Looking Statements Forward-Looking Statements This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMa

BioMarin Pharmaceutical Inc. (BMRN)

Exhibit 99.1 16-May-2025 BioMarin Pharmaceutical Inc. (BMRN) Business Update Call CORPORATE PARTICIPANTS Traci McCarty Group Vice President-Investor Relations, BioMarin Pharmaceutical Inc. Alexander Hardy President, Chief Executive Officer & Director, BioMarin Pharmaceutical Inc. Gregory Friberg Executive Vice President, Chief Research & Development Officer, BioMarin Pharmaceutical Inc. Brian R. M

Inozyme Acquisition: An Important Milestone • Deal builds on our 25-year legacy of developing innovative therapies for genetically defined conditions • Acquisition brings to BioMarin INZ-701, a Phase 3 enzyme replacement therapy for treatment of ENPP

Exhibit 99.1 Inozyme Acquisition May 19, 2025 1 Forward-Looking Statements Forward-Looking Statements This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMarin, including, without limitatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Offeror) (Name of Filing Persons (identifying status as offeror, issu

Email from Douglas A. Treco, Chief Executive Officer and Chairman of Inozyme Pharma, Inc., to employees on May 16, 2025 (incorporated by reference to Exhibit 99.1 of the Inozyme Pharma, Inc. Solicitation/Recommendation Statement on Schedule 14D-9-C filed with the Securities and Exchange Commission on May 16, 2025).

Exhibit 99.1 Subject: Important News: Inozyme to be Acquired by BioMarin Pharmaceutical Dear Inozyme Team, Today marks a significant milestone in our company’s journey. Coming just after our strong Q1 2025 earnings announcement, I’m writing to share with you that Inozyme has entered into a definitive agreement to be acquired by BioMarin Pharmaceutical, a global leader in rare disease therapies wit

BioMarin Pharmaceutical Inc. LinkedIn Post

Exhibit 99.3 BioMarin Pharmaceutical Inc. LinkedIn Post We’re excited to share that today we announced a definitive agreement to acquire Inozyme Pharma, a clinical-stage biopharmaceutical company advancing an innovative enzyme replacement therapy for ENPP1 Deficiency, a condition with no currently approved treatments. ENPP1 Deficiency is a rare, serious and progressive genetic condition that affec

BMRN-INZY Letter to BMRN Employees

Exhibit 99.1 BMRN-INZY Letter to BMRN Employees Subject: BioMarin to Acquire Inozyme Pharma To: BioMarin Employees Date: May 16, 2025 Dear BioMarin, Today marks an important milestone for BioMarin, with the announcement of our agreement to acquire Inozyme Pharma, which will add a Phase 3 enzyme replacement therapy to our portfolio. The therapy, INZ-701, treats ENPP1 deficiency, a rare and lifelong

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Offeror) (Name of Filing Persons (identifying status as offeror, issu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company) I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company) INOZYME PHARMA, INC. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 45790W108 (CUSIP Num

BMRN-INZY Letter to INZY Employees

Exhibit 99.2 BMRN-INZY Letter to INZY Employees To: Inozyme Employees Date: May 16, 2025 Dear Inozyme, I am reaching out today on behalf of BioMarin to share my excitement about the opportunity to bring INZ-701 to patients with ENPP1 Deficiency. Your team has done important work to evaluate the safety and efficacy profile of INZ-701, successfully advancing it into Phase 3 development. As I have go

AGREEMENT AND PLAN OF MERGER by and among: INOZYME PHARMA, INC., BIOMARIN PHARMACEUTICAL INC., INCLINE MERGER SUB, INC. Dated as of May 16, 2025

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: INOZYME PHARMA, INC., BIOMARIN PHARMACEUTICAL INC., and INCLINE MERGER SUB, INC. Dated as of May 16, 2025 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE 2 THE OFFER 16 Section 2.1 The Offer 16 Section 2.2 Company Actions 19 ARTICLE 3 MERGER TRANSACTION 21 Section 3.1 Merger of Merger Sub into the Company 21 Se

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Dat

Exhibit 99.1 BioMarin Contacts Inozyme Contacts Traci McCarty, Investors Stefan Riley, Investors BioMarin Pharmaceutical Inc. Inozyme Pharma, Inc. (415) 455-7558 (617) 461-2442 Marni Kottle, Media Todd Cooper, Media BioMarin Pharmaceutical Inc. Biongage Communications (415) 218-7111 (617) 840-1637 FOR IMMEDIATE RELEASE BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

TENDER AND SUPPORT AGREEMENT

Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”), dated as of May 16, 2025, is entered into by and between BioMarin Pharmaceutical Inc., a Delaware corporation (“Parent”), and the undersigned stockholder of Inozyme Pharma, Inc., a Delaware corporation (the “Company”), listed on Exhibit A hereto (the, “Stockholder”). Capitalized terms used but not defin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights - Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorab

EX-99.1 2 inzy-ex991.htm EX-99.1 Exhibit 99.1 Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights - Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quart

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Summary of Non-Employee Director Compensation Policy.

Exhibit 10.9 INOZYME PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Company’s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of Inozyme Pharma, Inc. (the “Company”). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and reta

Amendment No. 6 to Corporate Sponsored Research Agreement, dated December 19, 2024, by and between Yale University and the Registrant)

Exhibit 10.12 SIXTH AMENDMENT TO CORPORATE SPONSORED RESEARCH AGREEMENT This Sixth Amendment (the “Amendment”), effective as of December 19, 2024 (the “Amendment Effective Date”), is entered into by and Inozyme Pharma, Inc., a Delaware corporation, having its principal offices at 321 Summer Street, Suite 400, Boston, MA 02210 (“Inozyme”) and Yale University, a non-profit corporation organized and

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Inozyme Securities Corp. Massachusetts Inozyme Pharma Ireland Limited Ireland Inozyme Pharma Switzerland GmbH Switzerland

As filed with the Securities and Exchange Commission on March 10, 2025

As filed with the Securities and Exchange Commission on March 10, 2025 Registration No.

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticip

Exhibit 99.1 Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support ope

Amended and Restated Insider Trading Policy

Exhibit 19.1 INOZYME PHARMA, INC. AMENDED AND RESTATED INSIDER TRADING POLICY 1. BACKGROUND AND PURPOSE 1.1. Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or employee of Inozyme Pharma, Inc. (togeth

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) INOZYME PHARMA, INC.

JOINT FILING AGREEMENT

Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No.

CONTROL PERSON IDENTIFICATION

Exhibit B CONTROL PERSON IDENTIFICATION Samlyn Capital, LLC is the relevant entity for which Robert Pohly may be considered a control person.

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission F

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates - Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in

Exhibit 99.1 Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates - Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophosph

Legal disclaimer This presentation and any statements made orally during this presentation contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involve

Exhibit 99.2 Interim clinical and safety data of INZ-701 treatment in infants and young children with ENPP1 Deficiency and key program updates January 2025 Ella Living with ENPP1 Deficiency Legal disclaimer This presentation and any statements made orally during this presentation contain estimates and other statistical data made by independent parties and by us relating to market size and other da

INZY / Inozyme Pharma, Inc. / Affinity Asset Advisors, LLC - SCHEDULE 13G Passive Investment

SC 13G 1 inozymepharma-sc13g120224.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W 108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 Third

INZY / Inozyme Pharma, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment

SC 13G/A 1 eventideinozyme-sc13g.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY

Exhibit 99.1 Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission F

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD - - Company plans to initiate a registrational trial in calciphylaxis in 2025 subject to regulatory alignment and sufficient funding - BOSTON, Oct.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission F

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data f

Exhibit 99.1 Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Interim data from SEA

Up to $23,750,000 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275364 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 15, 2023) Up to $23,750,000 Common Stock We previously entered into an Open Market Sale AgreementSM, or sales agreement, with Jefferies LLC, or Jefferies, dated August 11, 2021, relating to the sale of shares of our common stock offered by this prospectus supplem

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fil

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Summary of Non-Employee Director Compensation Policy.

Exhibit 10.2 INOZYME PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Company’s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of Inozyme Pharma, Inc. (the “Company”). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and reta

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 20

Exhibit 99.1 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for second half of 2024 - - Cas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascul

Exhibit 99.1 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 INOZYME PHARMA, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fil

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights – Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701

Exhibit 99.1 Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights – Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in

Form of Restricted Stock Unit Agreement under the 2020 Stock Incentive Plan.

Exhibit 10.27 Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENT Granted under 2020 Stock Incentive Plan Inozyme Pharma, Inc. (the “Company”) hereby grants the following restricted stock units to the recipient named below pursuant to its 2020 Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof and incorporated her

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Inozyme Securities Corp. Massachusetts Inozyme Pharma Ireland Limited Ireland Inozyme Pharma Switzerland GmbH Switzerland

As filed with the Securities and Exchange Commission on March 12, 2024

As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.

Dodd-Frank Compensation Recovery Policy.

Exhibit 97.1 INOZYME PHARMA, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Inozyme Pharma, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall

Corporate Sponsored Research Agreement, dated January 6, 2017, by and between Yale University and the Registrant, as amended by Amendment No. 1 to Corporate Sponsored Research Agreement, dated February 19, 2019, by and between Yale University and the Registrant, as amended by Amendment No. 2 to Corporate Sponsored Research Agreement, effective December 31, 2021, by and between Yale University and the Registrant and as amended by Amendment No. 3 to Corporate Sponsored Research Agreement, dated May 31, 2022, by and between Yale University and the Registrant and as amended by Amendment No. 4 to Corporate Sponsored Research Agreement, dated March 24, 2023, by and between Yale University and the Registrant, and as amended by Amendment No. 5 to Corporate Sponsored Research Agreement, dated January 24, 2024, by and between Yale University and the Registrant.

Exhibit 10.11 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL YALE UNIVERSITY CORPORATE SPONSORED RESEARCH AGREEMENT This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) INOZYME PHARMA, INC.

INZY / Inozyme Pharma, Inc. / Sofinnova Venture Partners X, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45790W108 (CUSIP Number) Nathalie Auber Sofinnova Investments, Inc

INZY / Inozyme Pharma, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Inozyme Pharma, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

INZY / Inozyme Pharma, Inc. / Rock Springs Capital Management LP Passive Investment

SC 13G/A 1 rocksprings-inzy123123a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inozyme Pharma, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec

INZY / Inozyme Pharma, Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs

INZY / Inozyme Pharma, Inc. / SAMLYN CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

INZY / Inozyme Pharma, Inc. / New Enterprise Associates 15, L.P. - NEW ENTERPRISE ASSOCIATES 15, L.P. / INOZYME PHARMA -- 13G/A(#2E) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inozyme Pharma, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r

INZY / Inozyme Pharma, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm242424d19sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropri

INZY / Inozyme Pharma, Inc. / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-inzy123123a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inozyme Pharma, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check

INZY / Inozyme Pharma, Inc. / Pivotal bioVenture Partners Fund I, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d740462dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45790W108 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco,

INZY / Inozyme Pharma, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - INOZYME PHARMA, INC. Passive Investment

SC 13G/A 1 p24-0427sc13ga.htm INOZYME PHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check

INZY / Inozyme Pharma, Inc. / SPHERA FUNDS MANAGEMENT LTD. - SC 13G/A Passive Investment

SC 13G/A 1 zk2430878.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Inozyme Pharma Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

INZY / Inozyme Pharma, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) INOZYME PHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 45790W108 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the ru

INOZYME PHARMA, INC. 321 Summer Street, Suite 400 Boston, MA 02210

INOZYME PHARMA, INC. 321 Summer Street, Suite 400 Boston, MA 02210 November 13, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Inozyme Pharma, Inc. Registration Statement on Form S-3 File No. 333-275364 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461

Form of Senior Note

Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights – Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 of pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline d

Exhibit 99.1 Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights – Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 of pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in first quarter of 2

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inozyme Pharma, Inc.

Form of Senior Indenture

Exhibit 4.3 INOZYME PHARMA, INC. and Trustee INDENTURE Dated as of        SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.014.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Form of Subordinated Note

Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Form of Subordinated Indenture

Exhibit 4.4 INOZYME PHARMA, INC. and       Trustee INDENTURE Dated as of       SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4

As filed with the Securities and Exchange Commission on November 7, 2023

Table of Contents As filed with the Securities and Exchange Commission on November 7, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) - Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key b

Exhibit 99.1 Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) - Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in

INZY / Inozyme Pharma Inc / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) INOZYME PHARMA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45790W 108 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025

JOINT FILING AGREEMENT

EX-99.4 Exhibit 4 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the

INZY / Inozyme Pharma Inc / Pivotal bioVenture Partners Fund I, L.P. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45790W108 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights – Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma

Exhibit 99.1 Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights – Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pediatric pivotal trial for E

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Inozyme Pharma, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Inozyme Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39397 38-4024528 (State or other jurisdiction of incorporation) (Commission File

Underwriting Agreement, dated July 27, 2023, by and among Inozyme Pharma, Inc. and BofA Securities, Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the underwriters named therein

EX-1.1 Exhibit 1.1 INOZYME PHARMA, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: July 27, 2023 INOZYME PHARMA, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT July 27, 2023 BofA Securities, Inc. Cowen and Company, LLC Piper Sandler & Co. as Representatives of the several Underwriters c/o BofA Securities, Inc. On

12,500,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258702 PROSPECTUS SUPPLEMENT (To Prospectus dated August 23, 2021) 12,500,000 Shares Common Stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “INZY”. On July 27, 2023, the last reported sale price of our common stock on The Nasdaq Global

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

EX-99.1 Exhibit 99.1 Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock BOSTON, Mass., July 27, 2023 – Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the pricing of an underwritten public offering of 12,500,000

SUBJECT TO COMPLETION, DATED JULY 27, 2023

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258702 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency - Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal tri

EX-99.1 Exhibit 99.1 Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency - Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients - - ENERGY-3 pivotal trial in pediatric patients expected to initiate in October 2023, topline data expe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 INOZYME PHARMA, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

June 30, 2023

June 30, 2023 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39397) filed with the Securities and Exchange Commission on June 14, 2023).

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF INOZYME PHARMA, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings. 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 3 1.8 Adjournments 3 1.9 Voting and Proxies 4 1.10 Action at Meeting 4 1.11 Nomination of Directors 5 1.12 Notice of Busin

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

INZY / Inozyme Pharma Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INOZYME PHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 45790W108 (CUSIP Number) MAY 22, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th

INZY / Inozyme Pharma Inc / Pivotal bioVenture Partners Fund I, L.P. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45790W108 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Transition and Separation Letter Agreement, dated March 21, 2023, by and between the Registrant and Axel Bolte (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).

Exhibit 10.2 Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston, Massachusetts 02210 March 21, 2023 Axel Bolte [**] Dear Axel: As we have discussed, you are retiring and resigning from employment with Inozyme Pharma Switzerland GmbH (the “Company”), effective April 30, 2023 (the “Separation Date”). By countersigning and returning this letter agreement, you will be entering into a binding agre

Form of Nonstatutory Stock Option Agreement under 2023 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).

Exhibit 10.7 Inozyme Pharma, Inc. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2023 Inducement Stock Incentive Plan Inozyme Pharma, Inc. (the “Company”) hereby grants the following stock option to the recipient named below pursuant to its 2023 Inducement Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof and i

Form of Restricted Stock Unit Agreement under 2023 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).

Exhibit 10.8 Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENT Granted under 2023 Inducement Stock Incentive Plan Inozyme Pharma, Inc. (the “Company”) hereby grants the following restricted stock units to the recipient named below pursuant to its 2023 Inducement Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights - Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipate

Exhibit 99.1 Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights - Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 - BOSTON, May 9, 2023 – Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-

Employment Agreement, dated March 14, 2023, by and between the Registrant and Matthew Winton (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).

Exhibit 10.4 March 14, 2023 (revised) Matthew Winton, PhD [**] Dear Matthew: On behalf of Inozyme Pharma Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Letter Agreement”) is to summarize the terms of your employment with the Company, should you accept our offer: 1. Position and Duties. You will be employed to serve as Chief Operations

Employment Agreement, dated March 21, 2023, by and between the Registrant and Douglas Treco (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).

Exhibit 10.1 Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston, Massachusetts 02210 March 21, 2023 Doug Treco [**] Dear Doug: On behalf of Inozyme Pharma Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Letter Agreement”) is to summarize the terms of your employment with the Company, should you accept our offer: 1. Position and Dut

Summary of Non-Employee Director Compensation Policy.

Exhibit 10.5 INOZYME PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Company’s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of Inozyme Pharma, Inc. (the “Company”). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and reta

Consulting Agreement, dated April 30, 2023, by and between the Registrant and Axel Bolte (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).

Exhibit 10.3 Consulting Agreement This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Inozyme Pharma, Inc. (the “Company”) and Axel Bolte (the “Consultant”). WHEREAS, the Company desires to retain the services of the Consultant as a Senior Advisor to the Company and the Consultant desires to perform certain services for the C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

JOINT FILING AGREEMENT

EX-99.2 Exhibit 2 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: April 4, 2023 PIVOTA

INZY / Inozyme Pharma Inc / Pivotal bioVenture Partners Fund I, L.P. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45790W108 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name

2023 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-270733) filed with the Securities and Exchange Commission on March 22, 2023).

Exhibit 99.3 2023 INDUCEMENT STOCK INCENTIVE PLAN OF INOZYME PHARMA, INC. 1. Purpose The purpose of this 2023 Inducement Stock Incentive Plan (the “Plan”) of Inozyme Pharma, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contribution

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fil

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights - Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and re

Exhibit 99.1 Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights - Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and regulatory milestones remain on track with previous guidance - - Current cash, cash equivalents and short-term investments anticipated to f

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inozyme Pharma, Inc.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Inozyme Securities Corp. Massachusetts Inozyme Pharma Ireland Limited Ireland Inozyme Pharma Switzerland GmbH Switzerland

As filed with the Securities and Exchange Commission on March 22, 2023

As filed with the Securities and Exchange Commission on March 22, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fil

INZY / Inozyme Pharma Inc / SPHERA FUNDS MANAGEMENT LTD. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Inozyme Pharma Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) March 3, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐

Joint Filing Agreement by and among the Reporting Persons.

Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Inozyme Pharma Inc.

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Defic

Exhibit 99.1 Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial – - Rapid and significant increase in PPi observed in all dose cohorts with sustained increase observed in highest dose cohor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

INZY / Inozyme Pharma Inc / BAKER BROS. ADVISORS LP - SC 13G Passive Investment

SC 13G 1 tm234999d16sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

AGREEMENT

EX-99.1 2 tm234999d16ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Inozyme Pharma, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. ADVISOR

INZY / Inozyme Pharma Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm236635d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the a

INZY / Inozyme Pharma Inc / Rock Springs Capital Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

INZY / Inozyme Pharma Inc / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-inzy123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check

INZY / Inozyme Pharma Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment

SC 13G 1 inzy21323.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b

INZY / Inozyme Pharma Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

INZY / Inozyme Pharma Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - INOZYME PHARMA, INC. Passive Investment

Executive Transition, Separation, and Release of Claims Agreement, dated December 7, 2022 by and between Inozyme Pharma, Inc. and Henric Bjarke

EX-10.1 Exhibit 10.1 EXECUTIVE TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENT This Executive Transition, Separation, and Release of Claims Agreement (the “Agreement”) is made as of December 7, 2022 (the “Effective Date”) by and between Inozyme Pharma, Inc. (the “Company”) and Henric Bjarke (the “Executive”) (together, the “Parties”). WHEREAS, the Company and the Executive are parties to t

Consulting Agreement, dated December 7, 2022, by and between Inozyme Pharma, Inc. and Henric Bjarke

EX-10.2 Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Inozyme Pharma, Inc. (the “Company”) and Henric Bjarke (the “Consultant”). WHEREAS, the Company desires to retain the services of the Consultant and the Consultant desires to perform certain services for the Company; and WHEREAS, the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2022 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Inozyme Pharma,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates - Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – - Topline data from Phase 1/2 clinical tri

Exhibit 99.1 Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates - Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 ? - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023 ? - Liquidity and capital resources as of quarter end funds cash

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency –

Exhibit 99.1 Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency ? - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - Secured flexible debt facility for up to $70 millio

Corporate Sponsored Research Agreement, dated January 6, 2017, by and between Yale University and the Registrant, as amended by Amendment No. 1 to Corporate Sponsored Research Agreement, dated February 19, 2019, by and between Yale University and the Registrant, as amended by Amendment No. 2 to Corporate Sponsored Research Agreement, effective December 31, 2021, by and between Yale University and the Registrant and as amended by Amendment No. 3 to Corporate Sponsored Research Agreement, dated May 31, 2022, by and between Yale University and the Registrant.

Exhibit 10.2 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL YALE UNIVERSITY CORPORATE SPONSORED RESEARCH AGREEMENT This RESEARCH AGREEMENT (this ?Agreement?) is entered into as of January 6, 2017

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Loan and Security Agreement, dated July 25, 2022, by and among the Registrant, K2 HealthVentures LLC, as lender, K2 HealthVentures LLC, as administrative agent, and Ankura Trust Company, LLC, as collateral agent (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on August 15, 2022).

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) dat

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39397 (Commission File Number) 38-402

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) - Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all thre

Exhibit 99.1 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) - Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) ? - INZ-701 was generally well-tolerated and exhibited a favorable initial safety profile ?

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39397 (Commission File Number) 38-402

Form of Amended and Restated Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39397) filed with the Securities and Exchange Commission on June 10, 2022).

Exhibit 4.1 INOZYME PHARMA, Inc. AMENDED AND RESTATED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: April [], 2022 Amended and Restated Date: June [], 2022 Inozyme Pharma, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknow

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Employment Agreement, dated March 2, 2022, by and between the Registrant and Sanjay Subramanian (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 10, 2022).

Exhibit 10.1 March 2, 2022 Sanjay S. Subramanian Dear Sanjay: On behalf of Inozyme Pharma Inc. (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter (the ?Letter Agreement?) is to summarize the terms of your employment with the Company, should you accept our offer: 1. Position and Duties. You will be employed to serve as Senior Vice President, effective

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights – Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency – – Preliminary bioma

Exhibit 99.1 Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights ? Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency ? ? Preliminary biomarker and safety data from ongoing Phase 1/2 trial of INZ-701 in ABCC6 Deficiency on track for the second quarter of 2022 ? ? Cash, cash e

INZY / Inozyme Pharma Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45790W108 (CUSIP Number) April 19, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them.

INZY / Inozyme Pharma Inc / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) INOZYME PHARMA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45790W 108 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854

INZY / Inozyme Pharma Inc / Pivotal bioVenture Partners Fund I, L.P. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45790W108 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 d286815ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com

INZY / Inozyme Pharma Inc / Rock Springs Capital Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Form of Pre-Funded Warrant

Exhibit 4.1 INOZYME PHARMA, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: April [], 2022 Inozyme Pharma, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the ?Holder?) is entitle

Underwriting Agreement, dated April 14, 2022, by and among Inozyme Pharma, Inc. and Jefferies LLC and Cowen and Company, LLC, as representatives of the underwriters named therein

Exhibit 1.1 INOZYME PHARMA, INC. (a Delaware corporation) 16,276,987 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,523,013 Shares of Common Stock UNDERWRITING AGREEMENT April 14, 2022 JEFFERIES LLC COWEN AND COMPANY, LLC as Representatives of the several Underwriters JEFFERIES LLC 520 Madison Avenue New York, New York 10022 COWEN AND COMPANY, LLC 599 Lexington Avenue, 25th Floor New

Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market

Exhibit 99.1 Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market BOSTON, Mass., April 14, 2022 ? Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a pric

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 Inozyme Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39397 38-4024528 (State or other jurisdiction of incorporation) (Commission Fil

INZY / Inozyme Pharma Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

16,276,987 Shares of Common Stock Pre-Funded Warrants to Purchase 3,523,013 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258702 PROSPECTUS SUPPLEMENT (To Prospectus dated August 23, 2021) 16,276,987 Shares of Common Stock Pre-Funded Warrants to Purchase 3,523,013 Shares of Common Stock We are offering 16,276,987 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 3,523,013

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39397 (Commission File Number) 38-40

Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency - First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABC

Exhibit 99.1 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency - First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency ? - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of 2022 ? - Second cohort in Phase 1/2 clinical trial in ENPP1 Deficiency fully enrolled; to

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest d

Exhibit 99.1 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest dose cohort (0.2 mg/kg) ? - PPi increased in all three patients to levels comparable to those observed in a study of healthy subjects - -

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39397 (Commission File Number) 38-402

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Inozyme Securities Corp. Massachusetts Inozyme Pharma Ireland Limited Ireland Inozyme Pharma Switzerland GmbH Switzerland

Corporate Sponsored Research Agreement, dated January 6, 2017, by and between Yale University and the Registrant, as amended by Amendment No. 1 to Corporate Sponsored Research Agreement, dated February 19, 2019, by and between Yale University and the Registrant, as amended by Amendment No. 2 to Corporate Sponsored Research Agreement, effective December 31, 2021, by and between Yale University and the Registrant.

Exhibit 10.11 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL YALE UNIVERSITY CORPORATE SPONSORED RESEARCH AGREEMENT This RESEARCH AGREEMENT (this ?Agreement?) is entered into as of January 6, 2017

Separation Agreement, dated November 3, 2021, by and between the Registrant and Deborah Wenkert.

Exhibit 10.22 VIA ELECTRONIC MAIL November 3, 2021 (as revised on November 30, 2021) Deborah Wenkert, MD [**] Dear Deb: As we have discussed, you are separating from employment with Inozyme Pharma, Inc. (the ?Company?) for good reason, effective November 30, 2021 (the ?Separation Date?). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if

Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights – Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway - – Expect to enroll first patient in Phase 1/2 trial of INZ-701 for ABCC6 Deficien

Exhibit 99.1 Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights ? Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway - ? Expect to enroll first patient in Phase 1/2 trial of INZ-701 for ABCC6 Deficiency in the second quarter of 2022 - ? Preliminary safety and biomarker data from Phase 1/2 trials in ENPP1 Deficiency and ABCC6 Deficiency

As filed with the Securities and Exchange Commission on March 15, 2022

As filed with the Securities and Exchange Commission on March 15, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fil

Consulting Agreement, dated November 30, 2021, by and between the Registrant and Wenkert & Young, LLC.

Exhibit 10.23 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) is entered into and effective as of November 30, 2021 (the ?Effective Date?), by and between Inozyme Pharma, Inc., a Delaware corporation having a place of business at 321 Summer Street, Suite 400, Boston, MA 02210 (the ?Company?), and Wenkert & Young, LLC, a limited liability company having a place of business at [**]

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inozyme Pharma, Inc.

Inozyme Pharma Strengthens Management Team with Two Executive Appointments

Exhibit 99.1 Inozyme Pharma Strengthens Management Team with Two Executive Appointments BOSTON, MARCH 8, 2022 ? Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Sanjay S. Subramanian, M.S., MBA, as chief financial officer (CFO), effective as of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2022 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File Num

EX-99.1

EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.

INZY / Inozyme Pharma Inc / Pivotal bioVenture Partners Fund I, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

INZY / Inozyme Pharma Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

INZY / Inozyme Pharma Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - INOZYME PHARMA, INC. Passive Investment

SC 13G/A 1 p22-0618sc13ga.htm INOZYME PHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check

INZY / Inozyme Pharma Inc / New Enterprise Associates 15, L.P. - NEW ENTERPRISE ASSOCIATES 15, L.P. / INOZYME PHARMA -- 13GA(#1) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inozyme Pharma, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45790W108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r

ENPP1 clinical development strategy and illustrative goals for trials in adult and children patient populations Adults FIH Cohort 3 LATE STAGE STUDIES Dose: 1.8 mg/kg; n:3 Pending regulatory discussions and approval Cohort 2 Phase 1/2 DSMB Dose Phase

EX-99.1 2 d90613dex991.htm EX-99.1 Exhibit 99.1 ENPP1 clinical development strategy and illustrative goals for trials in adult and children patient populations Adults FIH Cohort 3 LATE STAGE STUDIES Dose: 1.8 mg/kg; n:3 Pending regulatory discussions and approval Cohort 2 Phase 1/2 DSMB Dose Phase 1/2 Extension – 48 weeks | Remain on Drug Dose: 0.6 mg/kg; n:3 Extension Selection Cohort 1 DSMB Phas

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission File

INZY / Inozyme Pharma Inc / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INOZYME PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45790W108 (CUSIP Number) November 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights – On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety da

Exhibit 99.1 Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights ? On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 ? ? Cash, cash equivalents, and investments expected to support continued operations into the first quarter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission

INOZYME PHARMA, INC. 321 Summer Street, Suite 400 Boston, MA 02210

INOZYME PHARMA, INC. 321 Summer Street, Suite 400 Boston, MA 02210 August 19, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Inozyme Pharma, Inc. Registration Statement on Form S-3 File No. 333-258702 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39397 INOZYME PHARMA, INC.

Open Market Sale AgreementSM, dated August 11, 2021, by and between the Registrant and Jefferies LLC (incorporated by reference into Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-258702) filed with the Securities and Exchange Commission on August 11, 2021).

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM August 11, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Inozyme Pharma, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common sto

Form of Senior Indenture

Exhibit 4.3 INOZYME PHARMA, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.014.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplica

Form of Senior Note

Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

As filed with the Securities and Exchange Commission on August 11, 2021

Table of Contents As filed with the Securities and Exchange Commission on August 11, 2021 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Inozyme Pharma, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39397 38-4024528 (State or Other Jurisdiction of Incorporation) (Commission Fi

Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights - Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency – - Clinical Trial Application in Europe accepte

Exhibit 99.1 Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights - Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency ? - Clinical Trial Application in Europe accepted for Phase 1/2 trial of INZ-701 in ABCC6 Deficiency ? - Investigational New Drug application in U.S. accepted for Phase 1/2 trial of INZ

Form of Subordinated Note

Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE